Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Michela Buonaiuto"'
Autor:
Mariella Cuomo, Lorena Coretti, Davide Costabile, Rosa Della Monica, Giulia De Riso, Michela Buonaiuto, Federica Trio, Carmela Bravaccio, Roberta Visconti, Roberto Berni Canani, Lorenzo Chiariotti, Francesca Lembo
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-9 (2023)
Abstract The gut-brain axis involves several bidirectional pathway communications including microbiome, bacterial metabolites, neurotransmitters as well as immune system and is perturbed both in brain and in gastrointestinal disorders. Consistently,
Externí odkaz:
https://doaj.org/article/d30f2e7126524298808cea87d3d9dd77
Autor:
Rosa Della Monica, Michela Buonaiuto, Mariella Cuomo, Cristina Pagano, Federica Trio, Davide Costabile, Giulia de Riso, Francesca Sveva Cicala, Maddalena Raia, Raduan Ahmed Franca, Marialaura Del Basso De Caro, Domenico Sorrentino, Giovanna Navarra, Laura Coppola, Lorella Tripodi, Lucio Pastore, Juergen Hench, Stephan Frank, Claudio Schonauer, Giuseppe Catapano, Maurizio Bifulco, Lorenzo Chiariotti, Roberta Visconti
Publikováno v:
Cell Death and Disease, Vol 14, Iss 9, Pp 1-13 (2023)
Abstract Despite intense research efforts, glioblastoma remains an incurable brain tumor with a dismal median survival time of 15 months. Thus, identifying new therapeutic targets is an urgent need. Here, we show that the lysine methyltransferase SET
Externí odkaz:
https://doaj.org/article/b44f13ef57b24faa81bbd847d68a87ec
Autor:
Mariella Cuomo, Ermanno Florio, Rosa Della Monica, Davide Costabile, Michela Buonaiuto, Teodolinda Di Risi, Giulia De Riso, Antonella Sarnataro, Sergio Cocozza, Roberta Visconti, Lorenzo Chiariotti
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-11 (2022)
Abstract FXYD1 is a key protein controlling ion channel transport. FXYD1 exerts its function by regulating Na+/K+-ATPase activity, mainly in brain and cardiac tissues. Alterations of the expression level of the FXYD1 protein cause diastolic dysfuncti
Externí odkaz:
https://doaj.org/article/723c168e91414290925a909beb7325af
Autor:
Cristina Pagano, Giovanna Navarra, Laura Coppola, Giorgio Avilia, Olga Pastorino, Rosa Della Monica, Michela Buonaiuto, Giovanni Torelli, Pasquale Caiazzo, Maurizio Bifulco, Chiara Laezza
Publikováno v:
Cell Death Discovery, Vol 8, Iss 1, Pp 1-11 (2022)
Abstract Targeting necroptosis is considered a promising therapeutic strategy in cancer, including Glioblastoma Multiforme (GBM), one of the most lethal brain tumors. Necroptosis is a mechanism of programmed cell death overcoming the apoptosis resist
Externí odkaz:
https://doaj.org/article/9166a92dd61f4d428fbb737702dede99
Autor:
Lucia Cannella, Rosa Della Monica, Antonella Lucia Marretta, Domenico Iervolino, Bruno Vincenzi, Anna Rosaria De Chiara, Ottavia Clemente, Michela Buonaiuto, Maria Luisa Barretta, Annabella Di Mauro, Massimiliano Di Marzo, Michele Guida, Giuseppe Badalamenti, Lorenzo Chiariotti, Salvatore Tafuto
Publikováno v:
Cells, Vol 12, Iss 12, p 1635 (2023)
Dacarbazine is an important drug in the therapeutic landscape of leiomyosarcoma (LMS). Alkylating agents are subjected to resistance mechanisms based on anti-apoptotic pathways and repair mechanisms, including the DNA repair enzyme O6-methylguanine-D
Externí odkaz:
https://doaj.org/article/0d9413f74d7d47d39e2e6cd7a6b7bfa3
Autor:
Liliana Montella, Nunzio Del Gaudio, Guglielmo Bove, Mariella Cuomo, Michela Buonaiuto, Davide Costabile, Roberta Visconti, Gaetano Facchini, Lucia Altucci, Lorenzo Chiariotti, Rosa Della Monica
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Glioblastomas are the most frequent and malignant brain tumor hallmarked by an invariably poor prognosis. They have been classically differentiated into primary isocitrate dehydrogenase 1 or 2 (IDH1 -2) wild-type (wt) glioblastoma (GBM) and secondary
Externí odkaz:
https://doaj.org/article/70f43cceeed8489eac57e87cf301a107
Autor:
Alfredo Marinelli, Mariella Cuomo, Raduan Ahmed Franca, Michela Buonaiuto, Davide Costabile, Cristina Pagano, Federica Trio, Liliana Montella, Maria Laura Del Basso De Caro, Roberta Visconti, Lorenzo Chiariotti, Rosa Della Monica
Publikováno v:
Brain Sciences, Vol 13, Iss 2, p 235 (2023)
Diagnoses of primary malignant mesenchymal brain tumors are a challenge for pathologists. Here, we report the case of a 52-year-old man with a primary brain tumor, histologically diagnosed as a high-grade glioma, not otherwise specified (NOS). The pa
Externí odkaz:
https://doaj.org/article/c97901a2bb884ddbaa4b39cb79f7f17c
Autor:
Teodolinda Di Risi, Mariella Cuomo, Roberta Vinciguerra, Sara Ferraro, Rosa Della Monica, Davide Costabile, Michela Buonaiuto, Federica Trio, Ettore Capoluongo, Roberta Visconti, Eleonora Riccio, Antonio Pisani, Lorenzo Chiariotti
Publikováno v:
International Journal of Molecular Sciences, Vol 23, Iss 20, p 12110 (2022)
Anderson–Fabry disease (FD) is an X-linked disease caused by a functional deficit of the α-galactosidase A enzyme. FD diagnosis relies on the clinical manifestations and research of GLA gene mutations. However, because of the lack of a clear genot
Externí odkaz:
https://doaj.org/article/8a5dd10d9f74462aa9f7dbebc1e12da4
Autor:
Rosa Della Monica, Mariella Cuomo, Michela Buonaiuto, Davide Costabile, Raduan Ahmed Franca, Marialaura Del Basso De Caro, Giuseppe Catapano, Lorenzo Chiariotti, Roberta Visconti
Publikováno v:
International Journal of Molecular Sciences, Vol 23, Iss 13, p 7148 (2022)
Epigenetic changes in DNA methylation contribute to the development of many diseases, including cancer. In glioblastoma multiforme, the most prevalent primary brain cancer and an incurable tumor with a median survival time of 15 months, a single epig
Externí odkaz:
https://doaj.org/article/cf0d41500ef6459dbf39595dec336ab1
Autor:
Tafuto, Lucia Cannella, Rosa Della Monica, Antonella Lucia Marretta, Domenico Iervolino, Bruno Vincenzi, Anna Rosaria De Chiara, Ottavia Clemente, Michela Buonaiuto, Maria Luisa Barretta, Annabella Di Mauro, Massimiliano Di Marzo, Michele Guida, Giuseppe Badalamenti, Lorenzo Chiariotti, Salvatore
Publikováno v:
Cells; Volume 12; Issue 12; Pages: 1635
Dacarbazine is an important drug in the therapeutic landscape of leiomyosarcoma (LMS). Alkylating agents are subjected to resistance mechanisms based on anti-apoptotic pathways and repair mechanisms, including the DNA repair enzyme O6-methylguanine-D